Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial

Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial

Abstract Objective Rosuvastatin plus ezetimibe improves the lipid-lowering effect through different mechanisms of action. This study intended to compare the efficacy and safety of the fixed-dose combination (FDC) of rosuvastatin/ezetimibe vs. rosuvastatin alone in hypercholesterolemia patients. Meth...

Full description

Saved in:
Bibliographic Details
Main Authors: Xianyou Ji, Jinlan Xia, Hong Zhang, Changjie Ren, Guang Ma, Shenwen Fu, Jun Zhang, Ying Chen, Xuebin Han, Jianming Zhang, Zhengxu Fang, Bo Yang, Baisong Yang, Wenjun Huang, Gang Yin, Hong Qi, Hao Gong, Dongfang Wang, Liuyi Hao, Xiufeng Zhao, Zhaohui Pei, Peijian Wang, Xiaodong Li, Ling Lin, De Li, Zhi Li, Lin Zhang, Bo Yin, Ying Cheng, Zhiqing You, Jianlong Sheng, Jie Wu, Ling Chen, Zhongcai Fan, Wang Zhao, Shuiping Zhao
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Lipids in Health and Disease
Subjects:
Hypercholesterolemia
Fixed-dose combination of rosuvastatin/ezetimibe
Rosuvastatin alone
Efficacy
Safety
Online Access:https://doi.org/10.1186/s12944-025-02670-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12944-025-02670-y

Similar Items